DDInter1467 DDInter1016
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Pimavanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pimavanserin may lead to a major life threatening interaction when taken with Toremifene
Pimavanserin may lead to a major life threatening interaction when taken with Vemurafenib